AllDocs -> cancers

CD5-PositveDiffuseLargeB-Cell Lymphoma Presenting in Bone Marrow without Lymphadenopathy Naoya Nakamura ,Tetsuo Kuze ,Yuko Hashimoto ,Yoko Hara , KazuoWatanabe ,TakanoriKawaguchi ,KazueiOgawa ,ShigeyukiAsano , Toshiaki Sai ,Shin Matsuda ,Hideo Sakuma and Masafumi Abe Departments ofPathology Internal Medicine,Fukushima Medical UniversitySchool ofMedicine,Fukushima Iwaki Kyoritsu General Hospital,Iwaki Ohta-Nishinouchi General Hospital,Koriyama In thisstudy,wereported fivecasesofCD5 diffuselargeB-celllymphoma (DLBCL)which initially presented as bone marrow involvement without lymphadenopathy. The cases involved two males and three females,with an average age of73.8 years. The patients had fever and showed general fatigue. Three of the five cases presented hepatosplenomegaly. Laboratory examination highlighted anemia, thrombocytopenia, presence or absence of leukopenia, hypoalbuminemia as well ...

Last Dance – Malignant Lymphoma in Ferrets Bruce H. Williams, DVM Diplomate, American College of Veterinary Pathologists Email: williamsb@afip.osd.mil Lymphoma – a swift silent killer. One day your ferret appears happy and healthy; the next day you notice a small hard lump under the jaw or by the leg. After a quick trip to the vet, you learn the sad truth – your beloved friend will soon be a cherished memory. In this third article on neoplasia in ferrets, let’s look at lymphoma - what it is, how it progresses so quickly, and why the results are so often tragic. Lymphoma is a neoplasm , an abnormal proliferation of cells beyond the body’s normal control mechanisms. In this case, lymphocytes, the cells which populate lymph nodes and control and execute many functions of the body’s immune system are the cells whose proliferation has ...

Annals of Nuclear Medicine Vol. 17, No. 5, 351–357, 2003 ORIGINAL ARTICLE Diagnosis of thyroid lymphoma and follow-up evaluation using Ga-67 scintigraphy Yoshihiro N ISHIYAMA , Yuka Y AMAMOTO , Koiku Y OKOE , Katashi S ATOH and Motoomi O HKAWA Department of Radiology, Faculty of Medicine, Kagawa Medical University A strong association between malignant lymphoma and Hashimoto’s thyroiditis has frequently been reported. However, it is difficult to detect the lymphomatous transformation of Hashimoto’s thyroiditis in the early stage. The purpose of the present study was to examine the usefulness of 67 Ga scintigraphy in the diagnosis and evaluation of the therapeutic effects during follow-up, in patients with a suspected diagnosis of primary thyroid lymphoma . Twenty-five patients who were suspected ...

Lymphoplasmacytoid Lymphoma Presenting as Severe Osteoporosis W. Atoyebi, 1 * M. Brown, 2 J. Wass, 2 T.J. Littlewood, 1 and C. Hatton 1 1 Department of Hematology, John Radcliffe Hospital, Oxford, United Kingdom 2 Department of Endocrinology and Metabolism, Nuf®eld Orthopedic Centre, Oxford, United Kingdom We report four cases presenting with severe osteoporosis which on further investigation were found to have an underlying lymphoplasmacytoid lymphoma (LPL). Common sec- ondary causes of osteoporosis were excluded in each case. Three of the cases re- sponded to treatment with a biphosphonate. As these lymphomas share some common pathological and clinical features with multiple myeloma (MM) an association with os- teoporosis is likely to represent more than a coincidental ®nding. ...

SPECIAL SERIES ARTICLE FINE NEEDLE ASPIRATION; DIAGNOSIS OF NODAL HODGKIN’S LYMPHOMA (PART II) A.R.Khan; Shuab Omer; Sumia Rashid; Syed Besina Abstract: 6620 lymph nodes were aspirated over 11 yr. period (Jan. 1991 - Dec. 2001) yielding 345 lymphomas. This included 90 cases of HL (26%). Out of these only 76 cases (84.4%) were diagnosed by FNA irrespective of sub typing. A suspicion of disease arose in 6 cases (6.7%). Smears were negative with picture of reactive lymphadenitis in another 8 cases (8.9%). This was attributed to scanty material in the aspirates. Subtyping attempted showed a correlation with histology in 50 cases (>55%). The cytohistopathologic correlation was best seen in lymphocyte predominant and mixed cellularity subtypes. Diagnosis and sub typing of NSHL was more difficult. There was only one case of lymphocyte depletion reticular disease correctly diagnosed on FNA. Most of ...

Strategic Plan For Addressing the Recommendations of the Leukemia, Lymphoma , and Myeloma Progress Review Group LLM-PRG Strategic Plan October 2002 1 Page 2 Message From the Director October 2002 In 2001, hematologic cancers-- as a group the fourth most common cancer -- claimed the lives of 60,300 Americans, drained the financial and emotional resources of hundreds of thousands, and continued to resist our best efforts to find a cure. Despite these tragic consequences, we are nevertheless increasing our scientific knowledge of this group of blood-related cancers and are using that knowledge to help reduce the burden. This year the death toll from hematologic cancers is expected to be 58,300 Americans. Continued scientific inquiry will yield unprecedented amounts of vital information essential to eliminating these diseases. ...

ABOUT US Patients Against Lymphoma is a not-for- profit organization founded in July of 2002 with the help and encouragement of many individuals – all directly affected by lymphoma . Better therapies are needed urgently to improve the survival and quality of life of patients living with lymphomas. Presently, 27,200 die of lymphoma each year in the United States , and many forms of lymphoma are incurable with the harsh chemo- and radio- therapies that are often given repeatedly with diminishing benefit. Lymphoma is a cancer that affects blood cells called lymphocytes , immune cells that protect you from viruses and bacteria, and even cancer. Damage to these cells can sometimes lead to abnormal cell behavior preventing the cells from dying when they should, or causing sustained rapid cell division. These malignant ...

Immunobiology of Cutaneous T Cell Lymphoma ( Berger, Cresswell, Edelson, Girardi, Glusac, Hanlon, Heald) For the past 17 years Richard Edelson, Chairman of the Department of Dermatology, has coordinated a broad based research program directed at the elucidation of the basic and clinically relevant properties of cutaneous T cell lymphoma (CTCL) cells. This program now has several interrelated components, integrating the contributions of investigators both inside and outside of Dermatology. The uniquely large referred CTCL patient base at Yale has facilitated a substantial number of clinical trials aimed at finding better treatments both for patients with "early" as well as with advanced disease. Richard Edelson, M.D. and Carole Berger, Ph.D. (Dermatology) have collaborated for over twenty years on studies of the biologic features of CTCL cells. Substantial progress has been made in identifying tumor specific antigens ...

The Studies of Pesticides and Lymphoma Alavanja, M.C. , Rush, G.A., Stewart, P., Blair, A. Proportionate mortality study of workers in the grain industry. Journal of the National Cancer Institute 78(2): 247–252 (Feb., 1987). Grain workers’ mortality rates from particular causes of death were studied using union insur- ance records. Information concerning pesticide use was also gathered. The authors found that pesticides used in the grain industry include aluminum phosphide (phosphine), carbon disul- fide, carbon tetrachloride, ethylene dibromide, ethylene dichloride, Malathion, and methyl bro- mide. In this study of the deaths of 1,114 white males, findings indicated increased risk of lym- phoma among grain mill workers (prompting a later study — see below). Mortality rates for several other types of cancer were also elevated. National Cancer Institute. ...

Lymphoma Research Foundation 8800 Venice boulevard, Suite 207 Los Angeles, CA 90034 (310) 204-7040 or (800) 500-9976 111 Broadway, 19th Floor New York, NY 10006 (212) 349-2910 or (800) 235 6948 www. lymphoma .org e-mail: helpline@ lymphoma .org The Wellness Community – National Office 919 18th St. NW, Suite LL54 Washington D.C., 20006 (202) 659-9709 or (888) 793-WELL www.thewellnesscommunity.org American Cancer Society, Inc. (800) ACS-2345 [(800) 227-2345] www.cancer.org American Pain Society 4700 West Lake Avenue Glenview, IL 60025 (847) 375-4715 www.ampainsoc.org Cancer Care, Inc. 1180 Avenue of the Americas New York, NY 10036 (800) 813-HOPE [(800) 813-4673] www.cancercare.org Cutaneous Lymphoma Network University of Cincinnati Hospital c/o Department of Dermatology 234 Goodman Street Pav-A-3 Cincinnati, ...

1 FINDING LYMPHOMA RESOURCES ON THE INTERNET Searching for cancer information on the Internet is often a challenge. This resource sheet will serve as a guide to help you research your lymphoma and treatment options by providing tips on: Lymphoma Resources including organizations dedicated to providing support and/or accurate, up-to-date information on Hodgkin’s disease and non-Hodgkin’s lymphoma . These sites may include disease-specific educational tools, support options, and links to related sites. General Cancer Resources/Cancer Support includes sites that maintain information and support on all cancers. Specific searches may be conducted for lymphoma on each site. Clinical Trials provides important information on how or where to search for clinical trials (investigational studies) on lymphoma . Drug Information including brand and generic names for each drug, when the ...

1 Guidelines for the use of Rituximab in Non-Hodgkin’s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin’s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection of lymphoid malignancies with a progressive increase in incidence with age. It is estimated that there will be 5800 new cases of Non-Hodgkin’s lymphoma in Canada with 195 of these in Nova Scotia in 1999. The low-grade lymphomas are predominantly B-cell tumours. Low-grade NHL is usually diagnosed as systemic disease and approximately 90% will have Stage III or IV disease. The majority of patients with indolent B-cell lymphoma have progressive disease and cannot be cured presently. Drug development for the treatment of low grade NHL has mainly focused on cytotoxic drugs. The natural history of the disease is not altered despite continued interventions with conventional single agent chemotherapy, ...

QC Form 0451 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7863.pdf Catalog #: 7863 – 5 µ g Concentration: 0.5 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Functional Analysis: All Human poly(A) RNAs undergo accelerated stability testing. RNA integrity is checked both before and after a 14–18 hour incubation at 37 ° C and is visualized on a 1% denaturing agarose gel. Poly(A) RNAs are functionally tested by Northern blot analysis using Ambion’s NorthernMax ™ Kit (Catalog #1940) and an anti- ...

QC Form 0447 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7857.pdf Catalog #: 7857 – 5 µ g Concentration: 0.5 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Functional Analysis: All Human poly(A) RNAs undergo accelerated stability testing. RNA integrity is checked both before and after 14–18 hour incubation at 37 ° C and is visualized on a 1% denaturing agarose gel. Poly(A) RNAs are functionally tested by Northern blot analysis using Ambion’s NorthernMax ™ Kit (Cat #1940) and an anti-sense ...

QC Form 0446 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7856.pdf Catalog #: 7856 – 100 µ g Concentration: 1 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Nonspecific Endonuclease/Nickase Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 300 ng of supercoiled plasmid DNA, analyzed on an agarose gel. Exonuclease Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 40 ng of 32 P-labeled Sau 3A fragments of pUC19, analyzed ...

QC Form 0450 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7862.pdf Catalog #: 7862 – 100 µ g Concentration: 1 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Nonspecific Endonuclease/Nickase Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 300 ng of supercoiled plasmid DNA, analyzed on an agarose gel. Exonuclease Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 40 ng of 32 P-labeled Sau 3A fragments of pUC19, analyzed ...

Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts Ulf Klein 1 , Annunziata Gloghini 2 , Gianluca Gaidano 3 , Amy Chadburn 4 , Ethel Cesarman 4 , Riccardo Dalla-Favera 1 , and Antonino Carbone 2 1 Institute for Cancer Genetics, and the Departments of Pathology and Genetics & Development, Columbia University, New York, NY10032, U.S.A. 2 Division of Pathology and Medical Oncology A, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy 3 Hematology Unit, Division of Internal Medicine, Department of Medical Sciences & IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy 4 Department of Pathology, ...

From the GRCA Health and Genetics Committee GOLDENS WITH LYMPHOMA AND OSTEOSARCOMA ARE NEEDED TO STUDY THE GENETIC BASIS OF LYMPHOMA AND OSTEOSARCOMA Most Golden Retriever fanciers know Goldens that have died of lymphoma (cancer of the lymph nodes, lymphosarcoma) and osteosarcoma (bone cancer). Since our Goldens are predisposed to these cancers, many of us have lost some of our own beloved Goldens to these diseases. The Canine Health Foundation has funded a study that may help determine the genetic basis of these cancers. We have hopes that this study and subsequent studies may some day lead to genetic tests to identify Goldens predisposed to developing lymphoma and bone cancer and may identify those lymphomas and bone cancers most likely to respond to treatment. If your Golden Retriever is newly diagnosed with lymphoma or osteosarcoma (has not yet started chemotherapy, including steroids), you ...

To Prevent and Cure Cancer T he Arizona Cancer Center’s Lymphoma Team is dedicated to finding a cure for the malignant lymphomas, including Hodgkin’s disease. In Arizona, an estimated 900 cases of Non-Hodgkin’s lymphoma alone will be diagnosed in the year 2000, and 400 patients will die from this disease. The Arizona Cancer Center is an internationally recognized leader in the study and treatment of the lymphomas. Collaborative research performed by Cancer Center investigators over the last 25 years has been critical in advancing the standard of care for patients with lymphoma in a number of ways, including refining the criteria for the diagnosis of lymphoma , identifying tumor features that can help predict outcome, finding targets for therapy, identifying standard treatments for previously untreated advanced and localized disease, and studying ways ...

Summer, 2002 GWCCS Cancer Support Group & Internet Resource Guide Page 1 www.gwccs.org Greater Washington Coalition for Cancer Survivors (202) 364-6422 Leukemia Support Groups SPONSOR GROUP/ DESCRIPTION MEETING DAY/TIME LOCATION CONTACT & PHONE STATE Inova Fairfax Hospital --- Life With Cancer Leukemia Education Support Group 2nd Thursday 7:15 – 9:00 PM LWC Family Center 2832 Juniper St. Merrifield Marsha Komandt (703) 698-2841 VA John Hopkins University Hospital Patients – Leukemia, Lymphoma , Mult Myeloma 1st/3rd Monday 2:00-3:00 PM Oncology Center Lounge Alease Johnson (410) 955-6765 MD John Hopkins University Hospital Family – Leukemia, Lymphoma , Mult Myeloma 1 st Thursday 4:00-5:00 PM Oncology Center Lounge ...

MOLECULAR ASSESSMENT OF GENE EXPRESSION IN B-CELL LYMPHOMA OF SIV INFECTED RHESUS MONKEYS ( MACACA MULATTA ). AN INTRODUC- TION. BODEMER, W., FLOTO, A., MÄTZ-RENSING, K. AND KAUP, F.-J. Key words: B-cell lymphoma , Simian immunodeficiency virus, HIV, oncogenic her- pesvirus, differential gene expression Abstract B-cell Non-Hodgkin’s lymphoma (B-NHL) is a typical tumor after infection with viruses causing immunodeficiency. Both, Simian as well as Human Immundeficien- cy Virus (SIV and HIV) are well known pathogens suspected to contribute to the de- velopment of B-cell lymphoma . Fortunately, macaques infected with SIV were shown to be an adequate non human primate model for NHL. In our group we established profound pathological examination protocols and identified classification markers. We conducted experiments to further insight into the molecular processes of lympho- magenesis. Presence of simian Epstein-Barr ...

68 NATURE MEDICINE • VOLUME 8 • NUMBER 1 • JANUARY 2002 ARTICLES Diffuse large B-cell lymphomas (DLBCLs) are the most common lymphoid neoplasms, composing 30–40% of adult non-Hodgkin lymphomas 1 . Although a subset of DLBCL patients are cured with current chemotherapeutic regimens, most succumb to the disease 2 . Clinical prognostic models such as the International Prognostic Index (IPI) have been developed to identify DLBCL patients who are unlikely to be cured with standard therapy 3 . However, the clinical factors of the IPI (age, performance status, stage, number of extranodal sites and serum lactate dehydroge- nase (LDH)) 3 are likely to be surrogate markers for the intrinsic molecular heterogeneity in this disease. Therefore, it is not sur- prising that IPI is imperfect in its identification of high-risk pa- ...

1 Supplementary Information for DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION BY GENE EXPRESSION PROFILING AND SUPERVISED MACHINE LEARNING Margaret A. Shipp, Ken N. Ross, Pablo Tamayo, Andrew P. Weng, Jeffery L. Kutok, Ricardo C. T. Aguiar, Michelle Gaasenbeek, Michael Angelo, Michael Reich, Geraldine S. Pinkus, Tane S. Ray, Margaret A. Koval, Kim W. Last, Andrew Norton, T. Andrew Lister, Jill Mesirov, Donna S. Neuberg, Eric S. Lander, Jon C. Aster, and Todd R. Golub December 6, 2001 Contents: Section I: Expanded Methods __ 3 Primary Lymphoma Specimens and Clinical Information _3 Microarray Hybridization_3 Preprocessing and Re-scaling _4 Supervised Learning4 Gene Marker Selection_5 Permutation Test and Neighborhood Analysis for Marker Genes _5 Algorithms__9 Weighted Voting 9 k-Nearest Neighbors (KNN) 9 Support Vector ...

ANSWERS ICD-O-3 Coding Exercise Lymphoma and Leukemia Histology Coding Diagnostic Statement Histology/Behavior Grade* 1. ANLL (acute non-lymphocytic leukemia) 9861/3 9 2. B-cell lymphoma 9591/3 6 3. AML t(8;21)(q22;q22) 9896/3 9 4. M2 acute myelocytic leukemia 9874/3 9 5. Mucosal associated lymphoid tissue (MALT) lymphoma 9699/3 9 6. Anaplastic large B-cell lymphoma 9680/3 6 7. Intravascular B-cell lymphoma 9680/3 6 8. Diffuse histiocytic lymphoma 9680/3 9 9. T-cell rich large B-cell lymphoma 9680/3 6 10. Centroblastic lymphoma 9680/3 9 11. Nodular lymphocyte predominant Hodgkin’s disease 9659/3 9 12. Diffuse lymphocyte predominance Hodgkin’s disease ...

Introduction The overall incidence of non-Hodgkin’s lym- phoma (NHL) has been rising during the past few decades. 1,2 According to the National Cancer Insti- tute,the incidence per 100,000 persons climbed from 8.5 in 1973 to 13.7 in 1987 — an increase of more than 50%. 3 The increase has been largely confined to two age groups:men 24 to 54 years of age and individ- uals = 65 years of age. 2 In fact, data from the Veterans Affairs medical system have shown that approximate- ly half of all NHLs now occur in individuals = 60 years of age. 4 Whereas the increase in NHLs among younger men is likely the result of the spread of the acquired immunodeficiency syndrome (AIDS), 5 reasons for the increase among older persons remain unclear. Cancer Control 5 Non-Hodgkin’s Lymphoma in the Elderly ...

500 MJA Vol 177 4 November 2002 NOTABLE CASES The Medical Journal of Australia ISSN: 0025-729X 4 November 2002 177 9 500-501 ©The Medical Journal of Australia 2002 www.mja.com.au Notable Cases A 63-year-old man with rheumatoid arthritis presented with pain and swelling of his right buttock. Imaging and tissue biopsy revealed a diffuse large B-cell, non-Hodgkin’s lymphoma . The disease- modifying drugs he was taking, cyclosporin and methotrexate, were stopped, and the lymphoma resolved spontaneously without the use of chemotherapy. (MJA 2002; 177: 500-507) R HEUMATOID ARTHRITIS is a common disorder. Its various articular and extra-articular manifestations are well described, but less well known is the association between rheumatoid arthritis and malignancy. There is an intrinsic risk of lymphoma , particularly non-Hodgkin’s lymphoma ...

All-Ireland cancer statistics 1994-96 91 Lymphoma 22. LYMPHOMA ICD-O.2 morphologies M9590/3-M9714/3 ICD-10 C81-C85 ICD-9 200-201, 202.0-202.2, 202.8 Lymphomas comprise a mixed group of neoplastic conditions that arise in lymphoreticular tissues, principally the lymph nodes, and typically occur as solid tumours in those tissues. They include Hodgkin’s disease (C81), follicular [nodular] non-Hodgkin’s lymphoma (NHL) (C82), diffuse NHL (C83), peripheral & cutaneous T-cell lymphomas (C84), and other/unspecified types of NHL (C85). Key facts • Average of 682 new cases per year, 1994-96: 317 in females, 365 in males. • Average of 340 deaths per year: 150 in females, 190 in males. • Age-standardised rates higher in males than females, by about 33% (incidence), 63% (mortality). • Incidence rate among males about 20% higher in Northern Ireland (NI) ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Non-Hodgkin’s Lymphoma (NHL) and Exposure to Ionizing Radiation 1 Non-Hodgkin’s Lymphoma (NHL) and (Lymphosarcoma and reticulum cell sarcoma) Exposure to Ionizing Radiation Summary : Some evidence has been recorded of a possible connection between non-Hodgkin's lymphoma and exposure to ionizing radiation. There is possible evidence from studies conducted at Los Alamos National Laboratory. Studies of nuclear workers at other sites who have been exposed to ionizing radiation and persons exposed to the atomic bomb show an increase risk of developing non-Hodgkin's lymphoma . The National Research Council’s BEIR V committee did not address the issue of radiation- induced non-Hodgkin’s lymphoma . Non-Hodgkin's lymphoma is designated as a “specified” cancer ...